226 related articles for article (PubMed ID: 34628478)
1. Inter-species interactions alter antibiotic efficacy in bacterial communities.
Bottery MJ; Matthews JL; Wood AJ; Johansen HK; Pitchford JW; Friman VP
ISME J; 2022 Mar; 16(3):812-821. PubMed ID: 34628478
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
3. Resistance evolution can disrupt antibiotic exposure protection through competitive exclusion of the protective species.
Quinn AM; Bottery MJ; Thompson H; Friman VP
ISME J; 2022 Oct; 16(10):2433-2447. PubMed ID: 35859161
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Cross-Feeding Inhibits Pathogen Growth in the Sputa of Patients with Cystic Fibrosis.
Flynn JM; Cameron LC; Wiggen TD; Dunitz JM; Harcombe WR; Hunter RC
mSphere; 2020 Apr; 5(2):. PubMed ID: 32350096
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
6. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y
Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940
[TBL] [Abstract][Full Text] [Related]
7. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
Cho HH; Kwon GC; Kim S; Koo SH
J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
[TBL] [Abstract][Full Text] [Related]
8. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
9. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
[TBL] [Abstract][Full Text] [Related]
10. Interplay of OpdP Porin and Chromosomal Carbapenemases in the Determination of Carbapenem Resistance/Susceptibility in Pseudomonas aeruginosa.
Atrissi J; Milan A; Bressan R; Lucafò M; Petix V; Busetti M; Dolzani L; Lagatolla C
Microbiol Spectr; 2021 Oct; 9(2):e0118621. PubMed ID: 34585948
[TBL] [Abstract][Full Text] [Related]
11. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa.
Hermes DM; Pormann Pitt C; Lutz L; Teixeira AB; Ribeiro VB; Netto B; Martins AF; Zavascki AP; Barth AL
J Med Microbiol; 2013 Aug; 62(Pt 8):1184-1189. PubMed ID: 23699064
[TBL] [Abstract][Full Text] [Related]
13. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
[TBL] [Abstract][Full Text] [Related]
16.
Orazi G; O'Toole GA
mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
[TBL] [Abstract][Full Text] [Related]
17. Bulgecin A as a β-lactam enhancer for carbapenem-resistant
Skalweit MJ; Li M
Drug Des Devel Ther; 2016; 10():3013-3020. PubMed ID: 27703329
[TBL] [Abstract][Full Text] [Related]
18. On the Offensive: the Role of Outer Membrane Vesicles in the Successful Dissemination of New Delhi Metallo-β-lactamase (NDM-1).
Martínez MMB; Bonomo RA; Vila AJ; Maffía PC; González LJ
mBio; 2021 Oct; 12(5):e0183621. PubMed ID: 34579567
[TBL] [Abstract][Full Text] [Related]
19. Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa.
López-Pérez M; Haro-Moreno JM; Molina-Pardines C; Ventero MP; Rodríguez JC
mSphere; 2021 Dec; 6(6):e0083621. PubMed ID: 34817240
[TBL] [Abstract][Full Text] [Related]
20. The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Saadh MJ; Lohrasbi A; Ghasemian E; Hashemian M; Etemad A; Dargahi Z; Kaviar VH
Yale J Biol Med; 2022 Dec; 95(4):495-506. PubMed ID: 36568834
[No Abstract] [Full Text] [Related]
[Next] [New Search]
